公开(公告)号：US20030195261A1

公开(公告)日：2003-10-16

申请号：US10395298

申请日：2003-03-25

Applicant: Sepracor Inc.

Inventor： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Qun K. Fang

IPC: A61K031/137

CPC classification number: A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutrarnine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.

Abstract translation: 公开了用于治疗和预防疾病和病症的方法，包括但不限于勃起功能障碍，情感障碍，体重增加，脑功能障碍，疼痛，强迫症，药物滥用，慢性障碍，焦虑，进食障碍 ，偏头痛和失禁。 所述方法包括施用多巴胺再摄取抑制剂和任选的另外的药理活性化合物。 还公开了包含多巴胺再摄取抑制剂和任选的另外的药理学活性化合物的药物组合物和剂型。 优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布睾胺代谢物及其药学上可接受的盐，溶剂化物和包合物。 优选的另外的药理活性化合物包括影响中枢神经系统的药物，例如5-HT <3> 拮抗剂。

公开(公告)号：US20030096792A1

公开(公告)日：2003-05-22

申请号：US10278097

申请日：2002-10-23

Applicant: Sepracor, Inc.

Inventor： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Qun K. Fang

IPC: A61K031/519 ,  A61K031/40 ,  A61K031/137

CPC classification number: A61K31/50 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K31/40 ,  A61K31/415 ,  A61K31/44 ,  A61K31/475 ,  A61K31/495 ,  A61K31/505 ,  A61K31/52 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

Abstract translation: 公开了用于治疗和预防疾病和病症的方法，例如但不限于：进食障碍; 体重增加; 肥胖; 过敏性肠综合征; 强迫症; 血小板粘附; 呼吸暂停 情感障碍，如注意力缺陷障碍，抑郁症和焦虑症; 男性和女性性功能障碍; 不安腿综合征 骨关节炎 药物滥用，包括尼古丁和可卡因成瘾; 发作性睡病 疼痛如神经性疼痛，糖尿病性神经病和慢性疼痛; 偏头痛 脑功能障碍; 慢性疾病如经前期综合征; 和失禁。 还公开了药物组合物和剂型，其包含外消旋或光学纯的西布曲明代谢物和任选的另外的药理活性化合物。

公开(公告)号：US20020188029A1

公开(公告)日：2002-12-12

申请号：US10000806

申请日：2001-12-04

Applicant: Sepracor Inc.

Inventor： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Qun K. Fang

IPC: A61K031/137

CPC classification number: A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.

Abstract translation: 公开了用于治疗和预防疾病和病症的方法，包括但不限于勃起功能障碍，情感障碍，体重增加，脑功能障碍，疼痛，强迫症，药物滥用，慢性障碍，焦虑，进食障碍 ，偏头痛和失禁。 所述方法包括施用多巴胺再摄取抑制剂和任选的另外的药理活性化合物。 还公开了包含多巴胺再摄取抑制剂和任选的另外的药理学活性化合物的药物组合物和剂型。 优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布曲明代谢物及其药学上可接受的盐，溶剂化物和包合物。 优选的额外的药理活性化合物包括影响中枢神经系统的药物，例如5-HT 3拮抗剂。